DG
FOLD

Delek Group’s Amicus Therapeutics FOLD Stock Holding History

Delek Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$12.4M Buy
1,021,096
+175,000
+21% +$2.22M 0.48% 75
2019
Q1 		$11.4M Sell
846,096
-1,112
-0.1% -$13.6K 0.48% 85
2018
Q4 		$8.33M Buy
847,208
+401,000
+90% +$4.41M 0.38% 92
2018
Q3 		$5.36M Buy
446,208
+126,208
+39% +$1.76M 0.23% 126
2018
Q2 		$5M Sell
320,000
-30,000
-9% -$454K 0.21% 131
2018
Q1 		$5.27M Buy
350,000
+240,000
+218% +$3.65M 0.27% 113
2017
Q4 		$1.58M Buy
+110,000
New +$1.51M 0.08% 166

Other funds holding FOLD

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Delek Group's FOLD Position: Q2 2019 in Review

Delek Group increased its Amicus Therapeutics (FOLD) stake by 21% in Q2 2019, buying an estimated $2.22M and bringing the position to 1,021,096 shares worth $12.4M. The position accounts for 0.48% of the portfolio, ranked #75.

Delek Group first reported a position in FOLD in Q4 2017 and has held it in 7 quarters since. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

  • Delek Group held 1,021,096 shares of Amicus Therapeutics worth $12.4M as of Q2 2019.
  • Delek Group bought 175,000 Amicus Therapeutics shares in Q2 2019, an estimated $2.22M.
  • Amicus Therapeutics made up 0.48% of Delek Group's portfolio in Q2 2019, its #75 holding.
  • Delek Group first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 7 quarters since.
  • 206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.